FATE News

Latest breaking news and updates for FATE stock.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:FATE) SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of i...

Compensation

10 days ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free def...

What potential risks or setbacks could arise from the fludarabine‑free approach that investors should monitor? How might this data influence partnerships or licensing opportunities with larger biotech/pharma firms? Are there any upcoming catalyst events (e.g., FDA meetings, conferences, data releases) that could drive volatility?

Clinical trials

about 1 month ago